This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Myotonic dystrophy type 1 (DM1)	Glycogen synthase kinase 3 β (GSK3B)	Mouse studies suggest inhibiting GSK3B could help treat DM1. In a mouse model of DM1, activated GSK3B was upregulated prior to the development of muscle weakness. In the mouse model, the nonspecific GSK3B inhibitor lithium increased muscle strength and decreased myotonia in skeletal muscles compared with no treatment. Next steps could include clinical testing of lithium or other GSK3B inhibitors in patients with DM1. Jeil Pharmaceutical Co. Ltd.'s GSK3B inhibitor, JGK-216/263, is in discovery to treat Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). SciBX 5(48); doi:10.1038/scibx.2012.1259 Published online Dec. 13, 2012	Findings unpatented; licensing status not applicable	Jones, K. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Nov. 19, 2012; doi:10.1172/JCI64081 Contact: Lubov T. Timchenko, Baylor College of Medicine, Houston, Texas e-mail: lubovt@bcm.tmc.edu